We are live on ! Find out more

Merck

MRK

Market cap $367B

148.78 USD

+0.80

0.54%

At close Updated Sep 25, 4:00 PM EDT

Pre-market

After hours

148.70

-0.08

0.05%

1 day

0.54%

5 days

1.36%

1 month

-4.9%

3 months

18.6%

6 months

24.64%

Year to date

39.77%

1 year

91.73%

5 years

102.81%

10 years

150.89%

About: Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

Employees: 75,000

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 58.3%

Neutral 33.7%

Negative 8%

Merck, Daiichi Sankyo withdraw US application for lung cancer drug

Merck and Daiichi ‌Sankyo have voluntarily withdrawn their ⁠US application seeking accelerated approval for their experimental lung ‌cancer ⁠therapy, the drugmakers said ⁠on Friday.

Merck, Daiichi Sankyo withdraw US application for lung cancer drug

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

RAHWAY, N.J.--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn. The decision to withdraw the BLA is based on discussions wit.

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

Zacks Investment Research

Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study

MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.

Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study

U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC).

U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)

Zacks Investment Research

Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?

Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.

Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?

Merck's eye disease drug meets main goal in trial

Merck said on Thursday ‌its drug met the main goal in a ⁠mid- to late-stage trial testing it in adult patients with a ‌type ⁠of disease that affects blood vessels at ⁠the back of the ⁠eye.

Merck's eye disease drug meets main goal in trial

Merck's Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). BRUNELLO is the first of two Phase 2b/3 trials evaluating the safety and efficacy of remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) path.

Merck's Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema

Zacks Investment Research

Merck (MRK) Declines More Than Market: Some Information for Investors

In the latest trading session, Merck (MRK) closed at $148.08, marking a -1.88% move from the previous day.

Merck (MRK) Declines More Than Market: Some Information for Investors

Proactive Investors

Merck pipeline seen driving potential re-rating as clinical catalysts approach

Merck & Co Inc (NYSE:MRK, XETRA:6MK) could see its shares re-rated as a series of clinical catalysts across its oncology and broader pipeline approach over the next 12 to 18 months, Bank of America (BofA) said while maintaining its 'buy' rating. The bank hosted investor meetings with Merck chief medical officer Eliav Barr, who conveyed confidence in the company's pipeline, with oncology and other programs providing multiple potential value-driving data readouts.

Merck pipeline seen driving potential re-rating as clinical catalysts approach

24/7 Wall Street

4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout

Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions.

4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout

See News Rankings

Price charts implemented using Lightweight Charts™